Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.

You may also be interested in...



"Best Buy" NSAID Rxs Up Since Vioxx Withdrawal, But Mobic Growing Faster, Consumers Union Says

Prescriptions for Abbott/Boehringer Ingelheim's Mobic doubled from September to March and the average retail price rose 9% in the same period, Consumers Union notes. Scripts for ibuprofen were up 28%, but prices were "relatively flat," the report says.

"Best Buy" NSAID Rxs Up Since Vioxx Withdrawal, But Mobic Growing Faster, Consumers Union Says

Prescriptions for Abbott/Boehringer Ingelheim's Mobic doubled from September to March and the average retail price rose 9% in the same period, Consumers Union notes. Scripts for ibuprofen were up 28%, but prices were "relatively flat," the report says.

Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns

Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel